I agree 100% PS. But every patch that gets sold by LMAT adds to the data of patients with Adapt tissue inside. It’s not important to us right now and would not impact is materially but still a nice to have in terms of data etc. Hopefully we get an Australian trial site as part of the TAVR trials next year that will assist with TGA approval for DurAVR.
I agree 100% PS. But every patch that gets sold by LMAT adds to...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.71 |
Change
0.010(0.06%) |
Mkt cap ! $301.9M | |||
| Open | High | Low | Value | Volume |
| $16.00 | $16.01 | $15.49 | $3.254M | 230.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $15.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 700 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |